Tracking and blocking interdependencies of cellular BRAF-MEK oncokinase activities

We are pleased to share news about a recently published TKFI paper by Jakob Fleischmann and his colleagues from the ONCOkinase lab.

This study centers on refining cancer treatments through targeted kinase therapy, with a specific focus on melanoma, a type of skin cancer. The researchers employed an advanced reporter system to precisely track the activity states of kinases in a cell culture model system. The study explored how the impact of drug combinations can be monitored by inhibiting two central oncokinases, BRAF and MEK1 respectively. The unique kinase reporter is thus suitable for identifying optimal drug combinations in the context of cancer mutation and, consequently, precision medicine.